Risk Stratification at Diagnosis: Gene Expression Profiling and Surveillance Planning

In this segment, our panel walks through the initial workup for a patient newly diagnosed with uveal melanoma, with a focus on how gene expression profiling and PRAME status are used to stratify patients by metastatic risk. You will hear how a validated GEP assay assigns patients to prognostic classes and how those classes directly inform surveillance decisions, including how frequently and with what imaging modality you should be monitoring your patients. The panel discusses the practical implications of a high-risk classification, including the case for liver MRI every three months, and how to communicate risk meaningfully to patients without overwhelming them at the time of diagnosis.